Actelion Ltd.'s Tracleer bosentan for pulmonary arterial hypertension sailed through its FDA advisory panel meeting on Friday. But the issues discussed during the meeting indicated that the company may not yet know the lowest efficacious dose, which could be important given that Tracleer has serious side effects.

The Cardiovascular and Renal Advisory Committee showed enthusiasm when it unanimously voted that the oral endothelin receptor A and B antagonist, developed by Actelion (SWX:ATLN, Allschwill, Switzerland) and partner Genentech Inc. (DNA, South San Francisco, Calif.), is approvable to treat PAH.